SCHEMBL5204866

SCHEMBL5204866

NC(=O)C#Cc1ccc2c(c1)OCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
GPR183 P32249 2/20 0.45
SMN1; SMN2 Q16637 6/20 0.44
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 1/20 0.44
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
CYP3A4 P08684 1/20 0.43
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
MAPT P10636 2/20 0.42
CTNNB1 P35222 1/20 0.42
WNT3A P56704 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5379969 0.85 ALDH1A1 (0.51) ALDH1A1MAPK1GPR183SMN1; SMN2NPC1
SCHEMBL16329717 0.83 MEN1 (0.47) ALDH1A1MAPK1GPR183SMN1; SMN2NPC1
SCHEMBL14907918 0.80 MEN1 (0.51) ALDH1A1GPR183SMN1; SMN2NPC1RAB9A
SCHEMBL861568 0.76 RAB9A (0.52) ALDH1A1GPR183SMN1; SMN2NPC1RAB9A
SCHEMBL8288520 0.74 GPR183 (0.56) ALDH1A1GPR183SMN1; SMN2NPC1RAB9A
SCHEMBL11491058 0.73 MAOB (0.62) ALDH1A1MAPK1GPR183SMN1; SMN2NPC1
SCHEMBL4656696 0.73 CYP3A4 (0.45) ALDH1A1MAPK1HTR3EHTR3BHTR3A
SCHEMBL2156716 0.72 ALDH1A1 (0.50) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL2155635 0.72 CYP3A4 (0.46) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL97197 0.72 NPC1 (0.48) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9453004-B2 Formylated xanthocillin analogues as neuroprotective agents NEURON BIOPHARMA, S.A. (ES) 2016-09-27 US disclosed
US-9453004-B2 Formylated xanthocillin analogues as neuroprotective agents NEURON BIOPHARMA, S.A. (ES) 2016-09-27 US disclosed
US-20150011621-A1 FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS NEURON BIOPHARMA, S.A. (ES) 2015-01-08 US disclosed
US-20150011621-A1 FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS NEURON BIOPHARMA, S.A. (ES) 2015-01-08 US disclosed
EP-1363925-B8 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2007-04-25 EP disclosed
EP-1363925-B1 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2006-11-15 EP disclosed
US-20060211636-A1 Macrolide Antibiotics ALIHODZIC SULEJMAN 2006-09-21 US disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 US disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 US disclosed
EP-1363925-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2003-11-26 EP disclosed
WO-2002050091-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 ALDH1A1 2549/4885MAPK1 3389/4885GPR183 980/4885
US-20060211636-A1 Macrolide Antibiotics IL1R1, MRPL12, RPS21 ALDH1A1 2549/4885MAPK1 3389/4885GPR183 980/4885
US-20150011621-A1 FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS FPR1, FPR2, FPR3 ALDH1A1 4607/4885MAPK1 3686/4885GPR183 2357/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 ALDH1A1 2482/4885MAPK1 2492/4885GPR183 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.